Integrating GLUT1 inhibition within the broader management plan for GDM-associated FGR would require a tailored approach, carefully balancing glucose control with the potential benefits of reducing placental oxidative stress and ferroptosis. The gene discussed is SLC2A1; the disease is gestational diabetes.